


# Mechanisms of antagonism of HIV-specific CD4+ T cell responses




# Problems

- Virus escape from immune recognition
- Antagonism of T cell responses



# Peptide-MHC-TCR interaction




# T cell antagonism

- Variants of a peptide recognized by a T cell can block recognition of the original peptide




# Classes of peptides



Alexander et al. J. Immunol 1993



# CD4+ T cell antagonism




Alexander et al., J Immunol 1993  
DeMagistris et al., Cell 1992  
Ostrov et al., J Immunol 1993  
Raciopi et al., J Exp Med 1993




# Mechanism of action of TCR antagonism

No dominant negative signal in CD8+ T cells


Dominant negative signal in CD4+ T cells



De Magistris et al.,  
Cell 1992



Daniels et al., J Immunol 1999  
Stotz et al., J Exp Med 1999




Robertson et al., J Immunol 1999




# Antagonism in HIV infection

Antagonism of CTL response in HIV



Klenerman et al., Nature 1994

Antagonism of HIV Vaccine response




Kent et al., J Immunol 1997



T cell antagonism by a variant peptide shorter than the full length epitope






# Viral peptide in HLA Binding Groove




Clone	HLA restriction	Minimum epitope
AC-01 Clone 1	DQ5	<b>EEKAFSPEVIP</b> (161-171)
AC-01 Clone 2	DQ7	<b>EPRGSDIAGT</b> (231-240)
AC-25 Clone 3	DR1	<b>PEVIPMSALSEGATP</b> (167-182)
161J Clone 4	DR4	<b>EVIPMFSAALS</b> (168-177)
CTS01 Clone 5	DQ7	<b>VHAGPIAPG</b> (219-227)



# Shorter peptide PG13 not active




# Antagonism by shorter peptide PG13





Why is the shorter peptide PG 13  
an antagonist?



# Tetramer staining





# PG 13 tetramer binds with less avidity than PP16




Does binding of shorter vs.  
longer peptide reveal function?













B



# Glycine turn abolished



# Engineered antagonist peptide



# Conclusions I


- Residues outside the MHC binding core can interact with and activate the T cell
- Partial T cell receptor engagement results in antagonism
- Antagonist peptide-MHC maintains ability to bind TCR with lower affinity than agonist



What gene pathways are disrupted after antagonist peptide exposure?



# STAT signaling pathway



# Activation truncated by antagonist

Time (min)





60

120





180

240



S  
T  
A  
T  
3




S  
T  
A  
T  
5




# Activation truncated by antagonist



# Multiplex detection of secreted cytokines



# Genes with 1.5 fold greater difference in expression between Ag and Ag+Ant




# IPA Comparison of gene array data


Annotated Function	p-Value	Predicted Activation State	Activation z-score	# Molecules
activation of T lymphocytes	2.93E-19		1.541	45
	6.31E-04		0.179	18
	6.09E-09	Decreased	-3.854	53
differentiation of lymphocytes	1.67E-23		1.442	59
	4.54E-04		-0.364	23
	6.73E-08		-1.987	64
expansion of T lymphocytes	3.65E-11		1.565	20
	3.05E-04		-0.057	10
	6.40E-05		0.969	23
proliferation of lymphocytes	3.88E-24		0.736	74
	9.01E-04		0.074	30
	7.01E-16		-1.965	109
proliferation of T lymphocytes	9.20E-26		0.753	69
	8.85E-04		-0.870	26
	5.10E-17		-1.099	98
T cell homeostasis	3.94E-21		1.157	57
	3.30E-04		-0.300	24
	7.70E-12		-1.233	76
function of T lymphocytes*	8.27E-17	Increased	2.064	36
	3.88E-06		-0.48	37
stimulation of leukocytes*	4.53E-13	Increased	3.173	24
	2.44E-05	Decreased	-2.971	24
stimulation of lymphocytes*	1.07E-14	Increased	3.128	22
	6.92E-06	Decreased	-2.296	22
stimulation of T lymphocytes*	1.74E-14	Increased	2.833	20
	4.31E-06	Decreased	-2.419	18




# IPA Comparison of gene array data



# Gene expression profile of T cell stimulation matches that of SIV vaccine trial



Fukazawa et al., Nat Med 2012



Jacobs et al., Retrovirology 2014



# Conclusions II

- Antagonism results in aborted activation due to a dominant negative signal
- Link to existing vaccine study where Ag + Ant treatment showed similar profile to vaccine failure



# Acknowledgments

## BSRI

- John Heitman
- Dale Hirschkorn
- Evan Jacobs

## Harvard

- Howell Moffett
- Margaret Clark
- Eric Rosenberg
- Bruce Walker

## University of Massachusetts

- Thomas Cameron
- Zarixia Zavala-Ruiz
- Jennifer Stone
- Larry Stern

## University of Toronto

- Des Persad
- Luoling Xu
- Longsi Ran
- David Kelvin

